Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02224768 · ClinicalTrials.gov registry record
YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey
A clinical trial, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- 158
- Enrollment target
NCT02224768: Completed study, sponsored by Bristol-Myers Squibb.
NCT02224768 is a clinical trial that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 158 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02224768 has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- 158 participants
- Enrollment target
Study Summary
To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
Primary Outcome
Distribution metrics and awareness of the tools from responses through the survey will be analysed and descriptive statistics will be used within the different participant groups
Interventions
- DRUG Ipilimumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 158 participants |
| Start Date | 2015-07 |
| Est. Completion | 2015-11 |
What the finished NCT02224768 record still lists
NCT02224768 is an observational study that tracks outcomes without assigning an intervention. The registered 158 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which Ipilimumab is the first listed.
NCT02224768 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02224768 about?
NCT02224768 is a clinical study titled "YERVOY® Risk Minimization Tool Effectiveness Evaluation Survey". To evaluate the effectiveness of the YERVOY® educational Risk Minimization (RM) tools in terms of awareness about these tools, their utilization, knowledge and comprehension of Immune Related Adverse Reaction (irAR)s, and appropriate behavior by Healthcare Professional (HCP)s and patients
What is the current status of trial NCT02224768?
This trial is currently completed. The enrollment target is 158 participants. The study started on 2015-07. Estimated completion is 2015-11.
What interventions are being tested in trial NCT02224768?
The interventions under investigation include: Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT02224768?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04486833 · 158 participants · Phase 1
Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib
- NCT04697966 · 158 participants · NA
Mechanisms and Predictors of Change in App-Based Mindfulness Training for Adolescents
- NCT04969835 · 158 participants · Phase 1
A Study Evaluating the Safety, Pharmacokinetics and Early Efficacy of AVA6000 in Solid Tumours
- NCT05230732 · 158 participants · NA
Neuromodulation of Inflammation and Endothelial Function
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia